Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Osiris Therapeutics

Evaluate

Thumbnail
October 02, 2020

Mesoblast can’t catch a break

Thumbnail
April 01, 2019

Smith & Nephew turns over a new Leaf

Article image
Vantage logo
March 13, 2019

Smith & Nephew buys Osiris and insists it has appetite for more

The UK ortho and woundcare group might yet pounce on Nuvasive.

Vantage logo
November 24, 2017

Upcoming events – Another SGLT2 approval due and stem cell data for Mesoblast

Vantage logo
March 30, 2015

Stryker and Osiris step into the bony void

Vantage logo
August 14, 2013

Stem cells get a win as Osiris's Grafix impresses in diabetic foot ulcers

Vantage logo
August 09, 2013

Teplizumab surprise puts spotlight on type 1 diabetes antibodies

Vantage logo
January 24, 2013

Liftoff for 2012’s big drug hopes

Vantage logo
November 15, 2012

Marqibo and Vascepa join Vitaros in biotech purgatory

Vantage logo
July 20, 2012

Key data readouts in the second half of 2012

Vantage logo
May 24, 2012

Stem cell therapies needing more regulatory acceptance

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up